WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2009. For the quarter, net sales were $297.5 million, a decline of 13.1% from $342.2 million in the third quarter of 2008, primarily driven by lower sales in the Preclinical Services (PCS) segment. Foreign currency translation reduced net sales by 1.8%. On a GAAP basis, net income for the third quarter of 2009 was $37.3 million, or $0.57 per diluted s
For more information, please visit
http://www.businesswire.com/news/home/20091103006695/en